Migraine news from Novartis – Phase III STRIVE study shows positive results
NHS England partners with Merck on a commercial agreement that allows people with MS in England immediate access to cladribine tablets (Mavenclad®)
News from Merck
Veriton Pharma Ltd – New company name for Special Products Ltd
Press release on behalf of Veriton Pharma LtdPublished online: 2/10/17 Veriton Pharma Ltd is announced as the new company name for Special Products Ltd. This name change has occurred both to incorporate the company’s past heritage with its future ambitions to make trusted medicines available for everyday living. The Chief Commercial Officer commented: With the launch of…
XXIII WCN 2017
Highlights from the World Congress of Neurology in Kyoto, Japan
Epistatus® 10 mg Oromucosal Solution Midazolam – Now Available To Prescribe
Press release on behalf of Special Products Ltd
Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years
Press release on behalf of Merck
Real-world data confirms clinical effectiveness of Zebinix®
Press release on behalf of Eisai and Bial
European Commission Grants Approval for Mavenclad (Cladribine Tablets)
First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Europe
MasterClass on the non-oral therapies and new NICE guideline for Parkinson’s
With publication of the new NICE guideline for Parkinson’s, Parkinson’s Academy is holding a series of roadshows exploring the non-oral therapy pathway in detail
